Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Green Tea Extract EGCG Blocks Amyloid Plaque Formation in Brain Cell Cultures

By BiotechDaily International staff writers
Posted on 20 Mar 2013
The green tea extract, (−)-epigallocatechin-3-gallate (EGCG) prevented formation of metal-associated amyloid-beta plaques in brain cell cultures and dissolved plaques that had already formed.

EGCG is the most abundant catechin in tea and is a potent antioxidant that may have therapeutic applications in the treatment of many disorders. It is found in green tea but not black tea.

Alzheimer's disease investigators at the University of Michigan (Ann Arbor, USA) investigated and compared the interaction and reactivity of EGCG with metal (copper and zinc) and metal-free A-beta species. Such a study was considered necessary, as chelation therapy, which involves the removal of heavy metals from the body, has been shown to be beneficial in lowering amyloid plaque levels. This is because A-beta aggregation is somewhat dependent on the metal ions copper and zinc, and A-beta deposition was impeded in transgenic mice treated with the antibiotic clioquinol, a known copper/zinc chelator.

In the current study, a team comprising chemists, biochemists, and biophysicists used advanced analytical techniques including ion mobility-mass spectrometry (IM-MS), two-dimensional NMR spectroscopy, and computational methods to study the interaction of EGCG and A-beta plaques in cultures of human brain cells.

They reported in the February 20, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that EGCG interacted with metal-A-beta species and formed small, unstructured A-beta aggregates more noticeably than in metal-free conditions. Incubation of cells with EGCG eliminated the toxicity presented by both metal-free A-beta and metal-A-beta plaques. EGCG bound to A-beta monomers and dimers, generating more compact peptide conformations than those from EGCG-untreated A-beta species and nontoxic ternary EGCG-metal-A-beta complexes were produced.

"A lot of people are very excited about this molecule," said senior author Dr. Mi Hee Lim, assistant professor of chemistry at the University of Michigan. "We used a multidisciplinary approach. This is the first example of structure-centric, multidisciplinary investigations by three principal investigators with three different areas of expertise. But we believe you have to have a lot of approaches working together, because the brain is very complex. We want to modify them [molecules like EGCG] for the brain, specifically to interfere with the plaques associated with Alzheimer's."

Related Links:

University of Michigan




comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.